Cargando…

Exploring the Control of PARP1 Levels in High-Grade Serous Ovarian Cancer

SIMPLE SUMMARY: In high-grade serous ovarian cancer (HGSOC), the PARP (poly(ADP-ribose) polymerase) inhibitor resistance limits the therapeutic strategies. Understanding the regulation of PARP1 expression in HGSOC may be functional to overcome this issue. We recently demonstrated that, in cervical c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raspaglio, Giuseppina, Buttarelli, Marianna, Cappoli, Natalia, Ciucci, Alessandra, Fagotti, Anna, Scambia, Giovanni, Gallo, Daniela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137242/ https://www.ncbi.nlm.nih.gov/pubmed/37190289 http://dx.doi.org/10.3390/cancers15082361

Ejemplares similares

Clinical Value of lncRNA MEG3 in High-Grade Serous Ovarian Cancer
por: Buttarelli, Marianna, et al.
Publicado: (2020)

Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients
por: Buttarelli, Marianna, et al.
Publicado: (2022)

Stat1 confers sensitivity to radiation in cervical cancer cells by controlling Parp1 levels: a new perspective for Parp1 inhibition
por: Raspaglio, Giuseppina, et al.
Publicado: (2021)

Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application
por: Ciucci, Alessandra, et al.
Publicado: (2022)

Ovarian low and high grade serous carcinomas: hidden divergent features in the tumor microenvironment
por: Ciucci, Alessandra, et al.
Publicado: (2016)

Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers
por: Ciucci, Alessandra, et al.
Publicado: (2016)

KLF7: a new candidate biomarker and therapeutic target for high-grade serous ovarian cancer
por: De Donato, Marta, et al.
Publicado: (2020)

What’s beyond BRCA Mutational Status in High Grade Serous Ovarian Cancer? The Impact of Hormone Receptor Expression in a Large BRCA-Profiled Ovarian Cancer Patient Series: A Retrospective Cohort Study
por: Perrone, Emanuele, et al.
Publicado: (2022)

A combined ANXA2-NDRG1-STAT1 gene signature predicts response to chemoradiotherapy in cervical cancer
por: Buttarelli, Marianna, et al.
Publicado: (2019)

Expression of the Glioma-Associated Oncogene Homolog 1 (Gli1) in Advanced Serous Ovarian Cancer Is Associated with Unfavorable Overall Survival
por: Ciucci, Alessandra, et al.
Publicado: (2013)

NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer
por: Marchetti, Claudia, et al.
Publicado: (2021)

Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer
por: Martinelli, Enrica, et al.
Publicado: (2018)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

The interaction of β-arrestin1 with talin1 driven by endothelin A receptor as a feature of α5β1 integrin activation in high-grade serous ovarian cancer
por: Masi, Ilenia, et al.
Publicado: (2023)

Pathological Chemotherapy Response Score in Patients Affected by High Grade Serous Ovarian Carcinoma: The Prognostic Role of Omental and Ovarian Residual Disease
por: Santoro, Angela, et al.
Publicado: (2019)

PD-L1 Expression on Circulating Tumour-Derived Microvesicles as a Complementary Tool for Stratification of High-Grade Serous Ovarian Cancer Patients
por: Battaglia, Alessandra, et al.
Publicado: (2021)

Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer
por: Sahin, Irem Durmaz, et al.
Publicado: (2019)

Trametinib response in heavily pretreated high-grade ovarian cancer: One step towards precision medicine
por: Cappuccio, Serena, et al.
Publicado: (2020)

PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer
por: Dickson, Kristie-Ann, et al.
Publicado: (2021)

Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells
por: Jia, Yaxun, et al.
Publicado: (2022)

Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system
por: Bound, Nirashaa T., et al.
Publicado: (2022)

Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer
por: Vendrell, Julie A., et al.
Publicado: (2023)

In search for biomarkers and potential drug targets for uterine serous endometrial cancer
por: Dinoi, Giorgia, et al.
Publicado: (2021)

Targeting tumor-stroma communication by blocking endothelin-1 receptors sensitizes high-grade serous ovarian cancer to PARP inhibition
por: Tocci, Piera, et al.
Publicado: (2023)

MiR-200c and HuR in ovarian cancer
por: Prislei, Silvia, et al.
Publicado: (2013)

Integration of PARP-inhibitors in ovarian cancer therapy
por: Pietragalla, Antonella, et al.
Publicado: (2020)

Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids
por: Cesari, Eleonora, et al.
Publicado: (2023)

Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
por: Kanakkanthara, Arun, et al.
Publicado: (2022)

CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors
por: Lu, Xue, et al.
Publicado: (2022)

High EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinoma
por: Jank, Paul, et al.
Publicado: (2023)

Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine
por: Nero, Camilla, et al.
Publicado: (2021)

Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP
por: Yokoyama, Takuhei, et al.
Publicado: (2017)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

Targeting the Microenvironment in High Grade Serous Ovarian Cancer
por: Nwani, Nkechiyere G., et al.
Publicado: (2018)

Role and prognostic significance of the epithelial-mesenchymal transition factor ZEB2 in ovarian cancer
por: Prislei, Silvia, et al.
Publicado: (2015)

Decreased Levels of GSH Are Associated with Platinum Resistance in High-Grade Serous Ovarian Cancer
por: Criscuolo, Daniela, et al.
Publicado: (2022)

Extreme complications related to bevacizumab use in the treatment of ovarian cancer: a case series from a III level referral centre and review of the literature
por: Turco, Luigi Carlo, et al.
Publicado: (2020)

The disruption of the CCDC6 – PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma
por: Morra, Francesco, et al.
Publicado: (2022)

Exploring the Role of Fallopian Ciliated Cells in the Pathogenesis of High-Grade Serous Ovarian Cancer
por: Coan, Michela, et al.
Publicado: (2018)

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas
por: Sadlecki, Pawel, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_c7m93jgug2p7b48no2k91gbv96